The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVFM | -6.5% | -100% | -92.75% | -100% |
| S&P | +16.23% | +94.45% | +14.22% | +141% |
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.83M | 16.0% |
| Gross Profit | $3.96M | 18.3% |
| Gross Margin | 82.13% | 1.6% |
| Market Cap | $1.11M | 70.5% |
| Market Cap / Employee | $0.03M | 0.0% |
| Employees | 32 | -13.5% |
| Net Income | -$1.78M | -232.1% |
| EBITDA | -$1.12M | 17.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.75M | 8.1% |
| Accounts Receivable | $4.93M | 6.9% |
| Inventory | 1.9 | 79.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.09M | 8800.0% |
| Short Term Debt | $47.22M | 8.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.33% | -588.5% |
| Return On Invested Capital | -36.32% | 105.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.92M | -156.0% |
| Operating Free Cash Flow | -$2.92M | -155.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.01 | -0.01 | -0.01 | -0.02 | 122.22% |
| Price to Sales | 0.05 | 0.05 | 3.20 | 0.07 | -93.14% |
| Price to Tangible Book Value | -0.01 | -0.01 | -0.01 | -0.01 | 102.78% |
| Enterprise Value to EBITDA | -23.31 | 880.26 | 172.94 | -47.03 | -1.54% |
| Total Debt | $44.78M | $45.97M | $45.73M | $47.31M | 9.02% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
